Alodokter
Indonesian app linking patients to doctors, pharmacy delivery, and insurance.
On the record
Checkpoint: Next funding round: institutional Series D would signal it can keep pace, another small angel tranche would not
The call
Alodokter keeps a working doctor and pharmacy network but is raising smaller checks while Halodoc raises bigger ones in the same fight.
Alodokter lets Indonesians chat with doctors online, fill prescriptions, and work with hospitals and insurance companies. It has built up a real network of 20,000 to 30,000 verified doctors and connections to 1,500+ hospitals that would be hard for a new competitor to copy overnight, but the app is losing the money race against Halodoc, which has raised five times more cash and claims about 40% of the market. The biggest threat is that free AI chatbots are starting to answer the symptom questions and health articles that used to bring new customers to Alodokter's door, and the company's funding has shrunk to small corporate checks instead of major investor rounds, suggesting the market thinks Alodokter cannot keep up. What could change everything: if Alodokter lands a large institutional funding round in the next year, it signals the market still believes it can compete; if it keeps raising small sums, the path likely leads to a buyout or slow fade.
Why
01
AI pressure: Generic chatbots like ChatGPT and Google AI health answers. Free AI answers to symptom questions can pull traffic away from the SEO content that feeds Alodokter's funnel. Could AI do the core job? Only partly.
02
Bigger players: Halodoc (Astra International and Gojek backed). Halodoc runs the same doctor chat, pharmacy, and insurance model with roughly five times the capital and a larger user base. Could a giant copy it? Yes, easily.
03
What protects it. Its verified doctor network, hospital and insurer integrations, and pharmacy delivery keep paying users inside the app after they arrive.
What would change this call
Alodokter closes an institutional Series D at an up valuation within 12 months. Would show investors believe it can still fund the arms race against Halodoc.
Another sub-$10M non-lead angel or corporate tranche for Alodokter in next 6-12 months. Would show the market is pricing acquisition or fade rather than standalone growth.
Halodoc publicly confirms an AI-triage feature live and reports consultation volume gains. Would show Halodoc converting AI capability into visible share taken from rivals like Alodokter.
Another sub-$10M non-lead angel or corporate tranche for Alodokter in next 6-12 months. Would show the market is pricing acquisition or fade rather than standalone growth.
Halodoc publicly confirms an AI-triage feature live and reports consultation volume gains. Would show Halodoc converting AI capability into visible share taken from rivals like Alodokter.
Key numbers
- $33M Series C raised
- $5.2M Series C-IV round
- 10M+ Google Play installs, 4.6 stars
Named risks
- Halodoc's 5x capital advantage and ~40% market share could squeeze Alodokter's acquisition costs and share.
- Funding cadence has shrunk to sub-$10M angel and corporate tranches since 2023, signaling limited institutional confidence.
- Generic LLM chatbots threaten Alodokter's SEO content and symptom-Q&A acquisition funnel.
- Indonesia's 2025 Digital Health Transformation Strategy and Personal Data Protection Law could raise compliance costs.
- Headcount data suggests possible contraction, with Growjo reporting a -14% YoY decline around 2022.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Halodoc | losing to | Halodoc holds ~40% Indonesia digital-outpatient share with $250M-plus raised vs Alodokter's ~$55.7M as of Sept 2025 |
| Halodoc | losing to | Alodokter's funding shrank to sub-$10M angel and corporate tranches in 2023-2025 while Halodoc raised ~$100M Series D in 2023 |
| MySiloam | contesting | Compared directly against Alodokter in a 2025 academic usability study of Indonesian telehealth platforms |
| Good Doctor | contesting | Cited as a direct Indonesian telehealth content and consultation competitor in 2025 usability research |
| KlikDokter | contesting | Named alongside Alodokter as competing Indonesian telehealth content platform in 2025 academic study |
Questions people ask
- Is Alodokter profitable in 2026?
- No public profitability data exists. Revenue estimates from data vendors conflict wildly, ranging from $8.53M (CB Insights, FY2022) to $25.5M (ZoomInfo) to $103.1M (Growjo, 2022), suggesting no audited financials are publicly disclosed as of 2026.
- Who is Alodokter's biggest competitor?
- Halodoc, an Astra International and Gojek-backed telehealth super-app with roughly 40% of Indonesia's digital outpatient market and over $250M raised including a ~$100M Series D in 2023, versus Alodokter's cumulative ~$55.7M raised as of September 2025.
- Could AI replace Alodokter?
- AI threatens Alodokter's SEO-driven health content and symptom Q&A funnel, which the company relies on for traffic, but its 20,000 to 30,000 verified doctors, 1,500-plus hospital integrations, and e-pharmacy logistics form a workflow moat that generic AI chatbots cannot replicate.
- How much funding has Alodokter raised?
- Alodokter has raised approximately $53 to $56.3 million cumulatively as of September 2025 per CB Insights and Caplight, far below rival Halodoc's reported $250M-plus, with its most recent rounds being small: $5.2M in February 2024 and an angel syndicate round in September 2025.
- Who owns Alodokter?
- Alodokter is privately held and venture-backed, founded in 2014 by CEO Nathanael Faibis and Co-founder/President Director Suci Arumsari, with investors including Sequis Life, Philips, MDI Ventures, Marubeni, Beacon Venture Capital, and AngelCentral syndicate members as of September 2025.
- Is Alodokter losing market share to Halodoc?
- Third-party competitive analysis from March 2026 places Halodoc at roughly 40% of Indonesia's digital outpatient market with 5 times Alodokter's capital, while Alodokter's funding has shrunk to small angel and corporate tranches since 2023, a pattern consistent with losing ground.
Timeline
- 2025-11-20CEO Nathanael Faibis speaks on AI Frontiers at La French Tech Indonesia AI Summit
- 2025-09Angel syndicate round led by AngelCentral closes for Alodokter
- 2024-05Partnership with FWD Insurance Indonesia announced for health-protection distribution
- 2024-02Series C-IV raises $5.2M from Beacon Venture Capital and HL Mando
- 2023-07Corporate Minority round raises $6M from Marubeni and Optima Health
- 2020-11Series C extension closes with MDI Ventures, Telkom Indonesia's CVC arm
- 2019-10Series C raises $33M led by Sequis Life with Philips and others
- 2017-11Series B raises approximately $9M led by SBVA and Golden Gate Ventures
- 2014Alodokter founded by Nathanael Faibis and Suci Arumsari
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Indonesia's healthcare superapp Alodokter raises $33M in Series C funding (2019-10-16)
- Revenue, Competitors, Alternatives (2022-04-19)
- Daily Markup 130: Indonesia's Alodokter raises Series C extension
- Alodokter Stock Price, Funding, Valuation, Revenue & Financial Statements (2025-09-17)
- $5.2M for Indonesian healthtech startup Alodokter
- cbinsights.com/company/alodokter (2025-09-22)
- AngelCentral Pimpin Investasi Sindikasi (2025-09-22)
- Chat Bersama Dokter, Apps on Google Play (2025-11-26)
- What is Competitive Landscape of Halodoc Company? (2026-03-20)
- Alodokter Employee Directory (2026-06-03)
- Alodokter Boosts Engagement by 45%
- Alodokter Witnesses 45% Uplift in Engagement using AI-based Campaign Optimization (2025-11-17)